Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT02196077

Public ClinicalTrials.gov record NCT02196077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD

Study identification

NCT ID
NCT02196077
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Enrollment
180 participants

Conditions and interventions

Interventions

  • BFF MDI 320/9.6 μg Drug
  • BFF MDI 160/9.6 μg Drug
  • BFF MDI 80/9.6 μg Drug
  • BD MDI 320 μg Drug
  • FF MDI 9.6 μg Drug

Drug

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2014
Primary completion
Feb 28, 2015
Completion
Feb 28, 2015
Last update posted
Jun 19, 2018

2014 – 2015

United States locations

U.S. sites
17
U.S. states
8
U.S. cities
17
Facility City State ZIP Site status
Pearl Investigative Site Rolling Hills Estates California
Pearl Investigative Site Clearwater Florida
Pearl Investigative Site Panama City Florida
Pearl Investigative Site Tampa Florida
Pearl Investigative Site Winter Park Florida
Pearl Investigative Site Edina Minnesota
Pearl Investigative Site Minneapolis Minnesota
Pearl Investigative Site Woodbury Minnesota
Pearl Investigative Site Saint Charles Missouri
Pearl Investigative Site Charlotte North Carolina
Pearl Investigative Site Cincinnati Ohio
Pearl Investigative Site Columbus Ohio
Pearl Investigative Site Dublin Ohio
Pearl Investigative Site Medford Oregon
Pearl Investigative Site Easley South Carolina
Pearl Investigative Site Greenville South Carolina
Pearl Investigative Site Spartanburg South Carolina

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02196077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 19, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02196077 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →